Day: February 8, 2021

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESTORONTO, Feb. 08, 2021 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (“Water Ways” or the “Company“), is pleased to announce that it has received its fifth commercial and first international order for its Medical Cannabis IOT Irrigation and fertilization system. The CAD$160,000 order was received from a Licensed Producer in Southern Africa who is currently building a 10,000 Square meters (approximately 110,000 Sq. ft.) Medical Cannabis Cultivation facility. The order was received through a greenhouse integrator who is building the complete facility.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/10798b2b-c5b6-4b37-8852-7c29610485b5The system is an Internet...

WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines.The availability of this COVID-19 affinity resin is the result of an accelerated program to provide COVID-19 vaccine manufacturers with a high purity capture step, decreasing processing time and significantly improving overall yield in the production of these critical vaccines.Working closely with Navigo Proteins...

•                          Basisindtjeningen før nedskrivninger i 2020 på 197,4 mio. kr., hvilket er et fald på 35,6 mio. kr.•                          Nedskrivninger på udlån m.v. udgør 38,1 mio. kr. Heri er indeholdt reservationer til tab som følge af COVID-19 på 39 mio. kr.•                          Beholdningsresultatet er på 36,1 mio. kr.•                          Årets resultat før skat udgør 195,4 mio. kr. og efter skat 153,2 mio. kr.•                          Resultatet før skat forrenter egenkapitalen med 9,8 %.•                          Likviditetsdækningen (LCR) er 429,5 %.•                          Kapitalprocenten er 21,0.•                          I 2021 forventes et resultat efter skat i niveauet 80-120 mio. kr.Vedhæftet filÅrsrapport 2020

              – Potential for two-pronged action against COVID-19 as an antiviral and anti-inflammatory agent supported by Phase 2 clinical study results –– Primary efficacy endpoint in hospitalized patients shows VERU-111 treatment had statistically significant 81% relative reduction in death or respiratory failure at Day 29 –– Statistically significant reduction in days in ICU; there was also a decrease in days on mechanical ventilation–MIAMI, Feb. 08, 2021 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company, today announced positive efficacy and safety results from a double-blind, randomized, placebo-controlled Phase 2 clinical trial evaluating oral, once-a-day dosing of VERU-111 versus placebo in approximately 40 hospitalized patients at high risk for Acute Respiratory Distress Syndrome (ARDS)...

MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today announced that fourth quarter and fiscal year 2020 financial results will be released after the market closes on Tuesday, February 23.Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 23 to discuss the results of the quarter and the fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13715783. A live webcast of the call will also be provided on the investor relations section of the Company’s website at investors.tactilemedical.com.For those unable to...

TOKYO, Feb. 08, 2021 (GLOBE NEWSWIRE) — Internet Initiative Japan Inc. (“IIJ”, TSE1: 3774) has corrected figures disclosed in its presentation material titled “Consolidated Financial Results for 1Q-3Q20 (April 1, 2020 to December 31, 2020)” which was disclosed at noon (JST) on February 8, 2021. The corrected points are underlined.CorrectionIn page 9 “II- 6. Systems Integration (SI), Systems Operation & Maintenance (recurring)” of our presentation material titled “Consolidated Financial Results for 1Q-3Q20 (April 1, 2020 to December 31, 2020).”[Before Correction]https://www.globenewswire.com/NewsRoom/AttachmentNg/da81bdb4-012a-4b11-8223-d92dfdc91d45[After Correction]https://www.globenewswire.com/NewsRoom/AttachmentNg/5ed734a0-d481-40ab-bff6-04f7db6d9f58About Internet Initiative Japan Inc.Founded in 1992, IIJ is one of Japan’s...

TOKYO, Feb. 08, 2021 (GLOBE NEWSWIRE) — Internet Initiative Japan Inc. (“IIJ”, TSE1: 3774) has corrected figures disclosed in its press release titled “IIJ Announces its Nine Months Financial Results for the Fiscal Year Ending March 31, 2021” which was disclosed at noon (JST) on February 8, 2021. The corrected points are underlined.CorrectionIn page 4 of our press release titled “IIJ Announces its Nine Months Financial Results for the Fiscal Year Ending March 31, 2021.”[Before Correction]Orders received for SI, including equipment sales, totaled JPY65,167 million, up 8.2% YoY (JPY60,231 million for 1Q-3Q19); orders received for systems construction and equipment sales were JPY23,943 million, up 2.7% YoY (JPY23,305 million for 1Q-3Q19), and orders received for systems operation and maintenance were JPY41,224 million, up 11.6% YoY...

– Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders –– CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation, and Degeneration 2021 conference on February 13, 2021 –ALPHARETTA, Ga., Feb. 08, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that numerous clinical presentations were delivered at the 44th Virtual Annual Macula Society Meeting which took place February 6-7, 2021. Clearside also announced that David M. Brown, M.D. will deliver a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD”...